Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women
Key claim: A trial will test whether weight loss from newer GLP-1 receptor agonists (semaglutide and tirzepatide) improves physical function, aging biomarkers, and vascular function in postmenopausal women with obesity.
Abstract
In postmenopausal women, obesity increases the risk of physical function decline, premature aging, and vascular dysfunction. Semaglutide and tirzepatide are potent obesity medications. The goal is to determine the effect of weight loss induced by the new generation of GLP-1 receptor agonists on physical function, aging biomarkers, and vascular function in postmenopausal women with obesity.
Why this matters
This is the first planned human trial to move GLP-1/GIP agonists beyond metabolic and cardiovascular endpoints into explicit geroscience readouts — physical function, aging biomarkers, vascular aging — in a population (postmenopausal women with obesity) where accelerated vascular aging is well documented. It marks a shift from mechanism-plausible reframing and mouse lifespan signals toward direct human healthspan testing of the AOM-as-geroprotector narrative that longevity clinics are already selling.